Research programme: prostaglandin E synthase inhibitors - Orexo

Drug Profile

Research programme: prostaglandin E synthase inhibitors - Orexo

Alternative Names: OX-MPI

Latest Information Update: 08 Aug 2014

Price : $50

At a glance

  • Originator Biolipox
  • Developer Biolipox; Boehringer Ingelheim
  • Class
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Pain; Rheumatoid arthritis
  • Discontinued Fever; Osteoarthritis

Most Recent Events

  • 06 Aug 2014 Boehringer Ingelheim terminates its license for research programme: prostaglandin E synthase inhibitors
  • 16 Dec 2010 This programme is still in active development
  • 08 Sep 2008 Orexo and Boehringer Ingelheim extend their research collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top